Aktienanalyse zu Glaukos Corp (GKOS)GKOSGlaukos Corp

Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company. The Company is focused on developing and commercializing therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Its commercial solutions and development-stage product candidates include procedural pharmaceuticals based on an intracameral drug delivery technology designed to reduce intraocular pressure (IOP) by delivering therapeutic levels of glaucoma medication from inside the eye over an extended period of time; Micro-Invasive Glaucoma Surgery (MIGS) products that primarily involve the insertion of a micro-scale device designed to reduce IOP by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma; bio-activated pharmaceuticals that are intended to strengthen, stabilize, and reshape the cornea for patients impacted by corneal ectatic disorders such as keratoconus, among others. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Glaukos Corp (GKOS) is a good buy right now due to its strong revenue growth, with Q2 2026 sales reaching $185.6 million, a 50% year-over-year increase, and a gross margin improvement to 81.67%. Additionally, analysts have set a price target of $210, indicating a potential upside of 27.4% from the current price of $164.84. However, the main risk is the negative sentiment from insider selling, with a 126.48% increase in selling activity over the last month, which could impact investor confidence.

10 analysts cover GKOS: 10 rate it Buy, 0 Hold and 0 Sell. The average price target is 127.08.